Andrea Taddei, Mechanistic Area Lead at BenevolentAI will be presenting at the ELRIG event on Artificial Intelligence - From Data to Drugs
ELRIG is a not for profit organisation, whose mission is to provide outstanding, leading edge knowledge to the life sciences community on an open access basis. ELRIG networking events are an extension of this ethos.
This presentation will give an overview of the various ways that AI is being applied to find new uses for existing drugs, as well as finding novel treatments for diseases. We will highlight where progress has been fast and where challenges (for example, data availability) still remain, making subtle, well placed references to how we are doing this along the way.
Andrea Taddei obtained his PhD in Molecular Medicine from the European School of Molecular Medicine (SEMM) at IFOM-IEO Campus in Milan. Subsequently, Andrea moved to Cancer Research UK and the Francis Crick Institute in London where he looked into developmental defects of the lymphatic system using lymphoedema animal models. He published as first and corresponding author on several peer-reviewed journals in the field of blood and lymphatic vascular biology. Andrea joined BenevolentAI in 2018 and leads one of the teams in drug discovery coordinating the end-to-end process from artificial intelligence-powered hypothesis generation to selection of candidates for chemistry optimisation.